ANTHEM Share Price | Anthem Biosciences Ltd Stock Analysis & Recommendation

Q: Is Anthem Bioscienc overvalued or undervalued?

As of 29 August 2025, the valuation grade for Anthem Bioscienc has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 90.82, a Price to Book Value of 18.59, and an EV to EBITDA ratio of 65.82. These ratios are considerably higher than its peers, such as Sun Pharma with a PE of 33.34 and Divi's Lab at 70.28, both of which are categorized as expensive or very expensive.In comparison to other companies in the pharmaceuticals and biotechnology sector, Anthem Bioscienc's high valuation metrics suggest that investors are paying a premium for its stock. The PEG ratio is notably at 0.00, which raises concerns about growth expectations not being met. While the stock has shown a positive return of 4.51% over the past month compared to a decline in the Sensex, the overall valuation still points to an overvaluation scenario.

Q: How has been the historical performance of Anthem Bioscienc?

Answer:The historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025.Breakdown:Anthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,356.72 Cr. The cash flow from operating activities saw a notable rise to 418.00 Cr from 140.00 Cr, contributing to a net cash inflow of 132.00 Cr, reversing the outflow of 158.00 Cr in the previous year. Overall, Anthem Bioscienc demonstrated robust growth in sales, profits, and cash flow, indicating a strong financial performance.

Q: Why is Anthem Biosciences Ltd falling/rising?

As of 28-Jan, Anthem Biosciences Ltd is experiencing a rise in its stock price, currently at 600.70, which reflects an increase of 8.65 (1.46%). This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector today by 0.98%, indicating a relatively stronger performance compared to its peers. Additionally, there has been a notable increase in investor participation, with a delivery volume of 1.38 lacs on 27 January, which is up by 37.48% compared to the 5-day average. However, it is important to note that despite the current rise, the stock is trading lower than its moving averages across various time frames (5-day, 20-day, 50-day, 100-day, and 200-day), suggesting that the overall trend may still be downward in the longer term. Furthermore, the stock is close to its 52-week low, being only 2.5% away from Rs 585.7. In summary, while Anthem Biosciences Ltd is currently rising due to improved sector performance and increased investor activity, it remains under pressure from its historical price levels and moving averages.

Upcoming Result: Anthem Bioscienc will declare its result soon on 05 Feb 2026

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.71 lacs (30.91%) Volume

Shareholding (Dec 2025)

FII

1.36%

Held by 48 FIIs

DII

0.27%

Held by 20 DIIs

Promoter

74.69%

Is Anthem Bioscienc overvalued or undervalued?

01-Sep-2025

As of August 29, 2025, Anthem Bioscienc is considered very expensive with a PE ratio of 90.82 and other high valuation metrics, indicating it is overvalued compared to peers, despite a recent positive return of 4.51%.

View full answer

How has been the historical performance of Anthem Bioscienc?

09-Nov-2025

Anthem Bioscienc experienced significant growth from March 2024 to March 2025, with net sales rising to 1,844.55 Cr and profit after tax increasing to 451.26 Cr. Key metrics such as operating profit and cash flow also improved, reflecting strong financial performance.

View full answer

When is the next results date for Anthem Biosciences Ltd?

28-Jan-2026

The next results date for Anthem Biosciences Ltd is February 5, 2026.

View full answer

Why is Anthem Biosciences Ltd falling/rising?

29-Jan-2026

As of 28-Jan, Anthem Biosciences Ltd is seeing a stock price increase to 600.70, driven by stronger sector performance and higher investor participation. However, it is still trading below its moving averages and near its 52-week low, indicating potential long-term downward pressure.

View full answer

Which are the latest news on Anthem Bioscienc?

29-Jan-2026

When is the next results date for Anthem Biosciences Ltd?
How has been the historical performance of Anthem Bioscienc?

Compare Anthem Bioscienc with Similar Stocks

Ajanta Pharma J B Chemicals &Ipca Labs

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 33,334 Cr (Large Cap)

P/E

65.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.34

Return on Equity

17.74%

Price to Book

11.82

Revenue and Profits:

Net Sales:

550 Cr

(Quarterly Results - Sep 2025)

Net Profit:

173 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-18.43%

6 Months

-24.23%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Anthem Bioscienc for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

When is the next results date for Anthem Biosciences Ltd?

The next results date for Anthem Biosciences Ltd is scheduled for February 5, 2026....

Read full news article

How has been the historical performance of Anthem Bioscienc?

Answer: The historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025. Breakdown: Anthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,35...

Read full news article

Announcements

No announcement available

Corporate Actions

BOARD MEETING

05 Feb 2026

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

29.80%

EBIT Growth (5y)

44.32%

EBIT to Interest (avg)

56.77

Debt to EBITDA (avg)

0.16

Net Debt to Equity (avg)

-0.25

Sales to Capital Employed (avg)

0.62

Tax Ratio

28.85%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

8.96%

ROCE (avg)

32.59%

ROE (avg)

19.93%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

11.55

EV to EBIT

52.32

EV to EBITDA

46.40

EV to Capital Employed

17.05

EV to Sales

17.37

PEG Ratio

Dividend Yield

ROCE (Latest)

32.59%

ROE (Latest)

17.74%

Technicals key factors

Indicator

Weekly

Monthly

No records

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 22 Schemes (6.89%)

FIIs

Held by 48 FIIs (1.36%)

Promoter with highest holding

Ajay Bhardwaj (42.53%)

Highest Public shareholder

Viridity Tone Llp (3.8%)

Individual Investors Holdings

9.6%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 2.64% vs 12.32% in Jun 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 33.77% vs 21.03% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "552.23",
          "val2": "538.01",
          "chgp": "2.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "225.66",
          "val2": "195.43",
          "chgp": "15.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.23",
          "val2": "1.61",
          "chgp": "38.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "198.43",
          "val2": "148.34",
          "chgp": "33.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "40.86%",
          "val2": "36.32%",
          "chgp": "4.54%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,090.24",
          "val2": "863.40",
          "chgp": "26.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "421.08",
          "val2": "324.04",
          "chgp": "29.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.84",
          "val2": "5.20",
          "chgp": "-26.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "346.77",
          "val2": "255.63",
          "chgp": "35.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "38.62%",
          "val2": "37.53%",
          "chgp": "1.09%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,342.38",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "522.15",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "7.30",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "378.19",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "38.90%",
          "val2": "NA%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,840.65",
          "val2": "1,417.54",
          "chgp": "29.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "689.01",
          "val2": "504.89",
          "chgp": "36.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "9.09",
          "val2": "9.14",
          "chgp": "-0.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "506.19",
          "val2": "374.78",
          "chgp": "35.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "37.43%",
          "val2": "35.62%",
          "chgp": "1.81%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

552.23

538.01

2.64%

Operating Profit (PBDIT) excl Other Income

225.66

195.43

15.47%

Interest

2.23

1.61

38.51%

Exceptional Items

0.00

Standalone Net Profit

198.43

148.34

33.77%

Operating Profit Margin (Excl OI)

40.86%

36.32%

4.54%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is 2.64% vs 12.32% in Jun 2025

Standalone Net Profit

QoQ Growth in quarter ended Sep 2025 is 33.77% vs 21.03% in Jun 2025

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

1,090.24

863.40

26.27%

Operating Profit (PBDIT) excl Other Income

421.08

324.04

29.95%

Interest

3.84

5.20

-26.15%

Exceptional Items

0.00

Standalone Net Profit

346.77

255.63

35.65%

Operating Profit Margin (Excl OI)

38.62%

37.53%

1.09%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Mar'25

Mar'25

Change(%)

Net Sales

1,342.38

Operating Profit (PBDIT) excl Other Income

522.15

Interest

7.30

Exceptional Items

0.00

Standalone Net Profit

378.19

Operating Profit Margin (Excl OI)

38.90%

NA%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Nine Monthly Results

Annual Results Snapshot (Standalone) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

1,840.65

1,417.54

29.85%

Operating Profit (PBDIT) excl Other Income

689.01

504.89

36.47%

Interest

9.09

9.14

-0.55%

Exceptional Items

0.00

Standalone Net Profit

506.19

374.78

35.06%

Operating Profit Margin (Excl OI)

37.43%

35.62%

1.81%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Annual Results

Company CV

About Anthem Biosciences Ltd

Anthem Biosciences Ltd

Large Cap

Pharmaceuticals & Biotechnology

Anthem Biosciences Limited was originally incorporated as "Anthem Biosciences Private Limited", dated June 13, 2006, issued by RoC. Subsequently, Company was converted from a Private Company to a Public Company , followed by the change in name of the Company to "Anthem Biosciences Limited" and a Certificate of Incorporation upon the conversion was issued by RoC on December 10, 2024.

Company Coordinates

No Company Details Available

Anthem Bioscienc

1Day

52 Week

CASH

FII

DII

Promoter

Is Anthem Bioscienc overvalued or undervalued?

Watch in Real-Time

How has been the historical performance of Anthem Bioscienc?

When is the next results date for Anthem Biosciences Ltd?

Why is Anthem Biosciences Ltd falling/rising?

Which are the latest news on Anthem Bioscienc?

Compare Anthem Bioscienc with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

Returns Beta

News

When is the next results date for Anthem Biosciences Ltd?

How has been the historical performance of Anthem Bioscienc?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ

Half Yearly Results Snapshot (Standalone) - Sep'25

Nine Monthly Results Snapshot (Standalone) - Mar'25

Annual Results Snapshot (Standalone) - Mar'25

About Anthem Biosciences Ltd

Company Coordinates